Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors.

F M Giardiello, J A Offerhaus, A C Tersmette, L M Hylind, A J Krush, J D Brensinger, S V Booker, S R Hamilton

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

BACKGROUND--Sulindac, a non-steroidal anti-inflammatory drug, causes regression of colorectal adenomas in patients with familial adenomatous polyposis (FAP) but the response is variable. Specific clinical factors predictive of sulindac induced regression have not been studied. METHODS--22 patients with FAP were given sulindac 150 mg orally twice a day. Polyp number and size were determined before treatment and at three months. The relation of nine clinical factors to polyp regression (per cent of baseline polyp number after treatment) was evaluated by univariate and multivariate analysis. RESULTS--After three months of sulindac, polyp number had decreased to 45 per cent of baseline and polyp size to 50 per cent of baseline (p < 0.001 and p < 0.01, respectively). Univariate analysis showed greater polyp regression in older patients (p = 0.004), those with previous colectomy and ileorectal anastomosis (p = 0.001), and patients without identifiable mutation of the APC gene responsible for FAP (p = 0.05). With multivariate regression analysis, response to sulindac treatment was associated with previous subtotal colectomy. CONCLUSIONS--Sulindac treatment seems effective in producing regression of colorectal adenomas of FAP patients with previous subtotal colectomy regardless of baseline polyp number and size. Changed sulindac metabolism, reduced area of the target mucosa, or changed epithelial characteristics after ileorectal anastomosis may explain these findings.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Hisamuddin, I. M., Wehbi, M. A., Schmotzer, B., Easley, K. A., Hylind, L. M., Giardiello, F. M., Yang, V. W. (2005). Genetic Polymorphisms of Flavin Monooxygenase 3 in Sulindac-Induced Regression of Colorectal Adenomas in Familial Adenomatous Polyposis. Cancer Epidemiol. Biomarkers Prev. 14: 2366-2369 [Abstract] [Full Text]  
• Koornstra, J. J., Rijcken, F. E.M., Oldenhuis, C. N.A.M., Zwart, N., van der Sluis, T., Hollema, H., deVries, E. G.E., Keller, J. J., Offerhaus, J. A., Giardiello, F. M., Kleibeuker, J. H. (2005). Sulindac Inhibits {beta}-Catenin Expression in Normal-Appearing Colon of Hereditary Nonpolyposis Colorectal Cancer and Familial Adenomatous Polyposis Patients. Cancer Epidemiol. Biomarkers Prev. 14: 1608-1612 [Abstract] [Full Text]  
• Brown, J. R., DuBois, R. N. (2005). COX-2: A Molecular Target for Colorectal Cancer Prevention. JCO 23: 2840-2855 [Abstract] [Full Text]  
• Hisamuddin, I. M., Wehbi, M. A., Chao, A., Wyre, H. W., Hylind, L. M., Giardiello, F. M., Yang, V. W. (2004). Genetic Polymorphisms of Human Flavin Monooxygenase 3 in Sulindac-Mediated Primary Chemoprevention of Familial Adenomatous Polyposis. Clin. Cancer Res. 10: 8357-8362 [Abstract] [Full Text]  
• Herendeen, J. M, Lindley, C. (2003). Use of NSAIDs for the Chemoprevention of Colorectal Cancer. The Annals of Pharmacotherapy 37: 1664-1674 [Abstract] [Full Text]  
• Yang, K., Fan, K., Kurihara, N., Shinozaki, H., Rigas, B., Augenlicht, L., Kopelovich, L., Edelmann, W., Kucherlapati, R., Lipkin, M. (2003). Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. Carcinogenesis 24: 605-611 [Abstract] [Full Text]  
• McEntee, M. F., Cates, J. M., Neilsen, N. (2002). Cyclooxygenase-2 Expression in Spontaneous Intestinal Neoplasia of Domestic Dogs. Vet Pathol 39: 428-436 [Abstract] [Full Text]  
• Keller, J. J., Offerhaus, G. J. A., Drillenburg, P., Caspers, E., Musler, A., Ristimaki, A., Giardiello, F. M. (2001). Molecular Analysis of Sulindac-resistant Adenomas in Familial Adenomatous Polyposis. Clin. Cancer Res. 7: 4000-4007 [Abstract] [Full Text]  
• Latham, P, Lund, E K, Brown, J C, Johnson, I T (2001). Effects of cellular redox balance on induction of apoptosis by eicosapentaenoic acid in HT29 colorectal adenocarcinoma cells and rat colon in vivo. Gut 49: 97-105 [Abstract] [Full Text]  
• Topping, D. L., Clifton, P. M. (2001). Short-Chain Fatty Acids and Human Colonic Function: Roles of Resistant Starch and Nonstarch Polysaccharides. Physiol. Rev. 81: 1031-1064 [Abstract] [Full Text]  
• Wollheim, F. A. (2000). Selective Cox-2 inhibition in man--therapeutic breakthrough or cosmetic advance?. Rheumatology (Oxford) 39: 935-938 [Full Text]  
• Goss, K. H., Groden, J. (2000). Biology of the Adenomatous Polyposis Coli Tumor Suppressor. JCO 18: 1967-1979 [Abstract] [Full Text]  
• de Jong, T. A., Skinner, S. A., Malcontenti-Wilson, C., Vogiagis, D., Bailey, M., van Driel, I. R., O'Brien, P. E. (2000). Inhibition of rat colon tumors by sulindac and sulindac sulfone is independent of K-ras (codon 12) mutation. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G266-G272 [Abstract] [Full Text]  
• Keller, J J, Offerhaus, G J A, Polak, M, Goodman, S N, Zahurak, M L, Hylind, L M, Hamilton, S R, Giardiello, F M (1999). Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut 45: 822-828 [Abstract] [Full Text]  
• Alberts, D. S. (1999). A Unifying Vision of Cancer Therapy for the 21st Century. JCO 17: 13-21 [Full Text]  
• Williamson, S. L.H., Kartheuser, A., Coaker, J., Kooshkghazi, M. D., Fodde, R., Burn, J., Mathers, J. C. (1999). Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis 20: 805-810 [Abstract] [Full Text]  
• McEntee, M. F., Chiu, C.-H., Whelan, J. (1999). Relationship of ß-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 20: 635-640 [Abstract] [Full Text]